Elite Pharmaceuticals, Inc. splits its revenue into 5 lines in its filings. The largest line in Q1 of fiscal 2027, the quarter ended Jun 30, 2026 was Direct Sales To Wholesalers at $16.4 million, 51% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q1 FY2027
Jun 30, 2026
|
Q4 FY2026
Mar 31, 2026
|
Q3 FY2026
Dec 31, 2025
|
Q2 FY2026
Sep 30, 2025
|
Q1 FY2026
Jun 30, 2025
|
Q4 FY2025
Mar 31, 2025
|
Q3 FY2025
Dec 31, 2024
|
Q2 FY2025
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
141
|
32
|
41
|
32
|
36
|
40
|
32
|
14
|
19
|
| Abbreviated New Drug Applications Revenue |
—
|
—
|
40
+28.1%
share 99.3%
|
31
+128.4%
share 99.3%
|
36
+98.6%
share 99.7%
|
—
|
32
share 98.7%
|
14
share 95.6%
|
18
share 96.5%
|
| Direct Sales To Wholesalers |
63
share 44.4%
|
16
-13.8%
share 50.7%
|
—
|
—
|
—
|
19
share 47.3%
|
—
|
—
|
—
|
| Indirect Sales To Wholesalers |
78
share 55.0%
|
16
share 48.6%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Unscheduled Products Licensing Fees |
—
|
—
|
—
|
—
|
—
|
0
share 1.1%
|
—
|
—
|
—
|
| Licensing |
1
-60.2%
share 0.6%
|
0
-49.0%
share 0.7%
|
0
-29.2%
share 0.7%
|
0
-67.2%
share 0.7%
|
0
-80.9%
share 0.3%
|
0
share 1.1%
|
0
share 1.3%
|
1
share 4.4%
|
1
share 3.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ELTP (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- NJ
- Headquarters
- Northvale, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1053369
- Former names
- ELITE PHARMACEUTICALS INC /DE/ (until Feb 8, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.